The Ritm Group has been established to co-ordinate the global group of companies that market and sell the genuine Scenar technology. Helen Gracie; the Market Development Director for Ritm America commented recently on the recent Institute of Medicine report on the prevalence and cost of chronic pain in America.
It would be interesting to know the true cost of pain in Australia in terms of productivity, medical costs and lost work. It would be even more interesting if there was a focus on TGA approved treatment options that are non invasive and are without side effects. Perhaps the first Australian National Pain Week to be held July 24 – 30 2011 will help highlight the recent progress made by industry and specifically the Ritm Group to help address this growing health, social and economic problem.